Key Points
- Beth Hecht sold 16,667 shares of Xeris on May 1 at an average price of $6.23 for roughly $103,835, cutting her stake by 1.38% to 1,193,173 shares; the sale was executed under a pre-arranged Rule 10b5-1 plan and follows identical monthly 16,667-share disposals in Feb–Apr.
- Xeris Biopharma has a $1.08 billion market cap and a 52‑week range of $4.26–$10.08, reported $0.06 EPS (beating estimates) while revenue slightly missed, and carries a consensus analyst rating of Moderate Buy with a $10.80 price target.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $6.23, for a total transaction of $103,835.41. Following the transaction, the insider directly owned 1,193,173 shares in the company, valued at approximately $7,433,467.79. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Beth Hecht also recently made the following trade(s):
- On Wednesday, April 1st, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $5.99, for a total transaction of $99,835.33.
- On Monday, March 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $6.25, for a total transaction of $104,168.75.
- On Monday, February 2nd, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.45, for a total transaction of $124,169.15.
Xeris Biopharma Stock Performance
XERS opened at $6.28 on Friday. The company has a quick ratio of 1.57, a current ratio of 2.19 and a debt-to-equity ratio of 16.10. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -627.37 and a beta of 0.85. Xeris Biopharma Holdings, Inc. has a 52-week low of $4.26 and a 52-week high of $10.08. The firm's fifty day simple moving average is $5.93 and its two-hundred day simple moving average is $7.03.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Monday, March 2nd. The company reported $0.06 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.03. The business had revenue of $85.81 million during the quarter, compared to analysts' expectations of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. Equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.
Institutional Trading of Xeris Biopharma
Several institutional investors have recently modified their holdings of XERS. UBS Group AG lifted its position in shares of Xeris Biopharma by 682.4% during the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company's stock worth $14,511,000 after buying an additional 1,554,869 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company's stock worth $87,815,000 after buying an additional 1,358,760 shares during the last quarter. Qube Research & Technologies Ltd lifted its position in shares of Xeris Biopharma by 67.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company's stock worth $14,429,000 after buying an additional 1,245,188 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company's stock worth $15,317,000 after buying an additional 1,199,435 shares during the last quarter. Finally, Granahan Investment Management LLC raised its position in Xeris Biopharma by 249.4% in the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company's stock valued at $9,604,000 after purchasing an additional 873,236 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on XERS shares. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Xeris Biopharma in a report on Monday, March 2nd. Weiss Ratings upgraded shares of Xeris Biopharma from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Wednesday, March 4th. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a "buy" rating to a "strong-buy" rating in a research note on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $10.80.
Read Our Latest Stock Report on XERS
About Xeris Biopharma
(
Get Free Report)
Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company's proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.
The company's flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
